|
1
|
Karpińska-Kaczmarczyk K, Lewandowska M,
Białek A, Ławniczak M and Urasińska E: Gastric hyperplastic polyps
coexisting with early gastric cancers, adenoma and neuroendocrine
cell hyperplasia. Pol J Pathol. 67:33–38. 2016. View Article : Google Scholar
|
|
2
|
Jung Y, Park J, Bang YJ and Kim TY: Gene
silencing of TSPYL5 mediated by aberrant promoter methylation in
gastric cancers. Lab Invest. 88:153–160. 2008. View Article : Google Scholar
|
|
3
|
Ushijima T and Sasako M: Focus on gastric
cancer. Cancer Cell. 5:121–125. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Smith MG, Hold GL, Tahara E and El-Omar
EM: Cellular and molecular aspects of gastric cancer. World J
Gastroenterol. 12:2979–2990. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Panani AD: Cytogenetic and molecular
aspects of gastric cancer: Clinical implications. Cancer Lett.
266:99–115. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maxwell AW, Wood S and Dupuy DE: Primary
extraskeletal Ewing sarcoma of the stomach: A rare disease in an
uncommon location. Clin Imaging. 40:843–845. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hobert O: Gene regulation by transcription
factors and microRNAs. Science. 319:1785–1786. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Glud M, Rossing M, Hother C, Holst L,
Hastrup N, Nielsen FC, Gniadecki R and Drzewiecki KT:
Downregulation of miR-125b in metastatic cutaneous malignant
melanoma. Melanoma Res. 20:479–484. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ueda T, Volinia S, Okumura H, Shimizu M,
Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al:
Relation between microRNA expression and progression and prognosis
of gastric cancer: A microRNA expression analysis. Lancet Oncol.
11:136–146. 2010. View Article : Google Scholar
|
|
11
|
Croce C: Introduction to the role of
microRNAs in cancer diagnosis, prognosis, and treatment. Cancer J.
18:213–214. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nikitina EG, Urazova LN and Stegny VN:
MicroRNAs and human cancer. Exp Oncol. 34:2–8. 2012.PubMed/NCBI
|
|
13
|
Holley CL and Topkara VK: An introduction
to small non-coding RNAs: miRNA and snoRNA. Cardiovasc Drugs Ther.
25:151–159. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baroni D and Arrigo P: MicroRNA target and
gene validation in viruses and bacteria. Methods Mol Biol.
1107:223–231. 2014. View Article : Google Scholar
|
|
15
|
Sim J, Ahn H, Abdul R, Kim H, Yi KJ, Chung
YM, Chung MS, Paik SS, Song YS and Jang K: High MicroRNA-370
expression correlates with tumor progression and poor prognosis in
breast cancer. J Breast Cancer. 18:323–328. 2015. View Article : Google Scholar
|
|
16
|
Duan N, Hu X, Yang X, Cheng H and Zhang W:
MicroRNA-370 directly targets FOXM1 to inhibit cell growth and
metastasis in osteosarcoma cells. Int J Clin Exp Pathol.
8:10250–10260. 2015.PubMed/NCBI
|
|
17
|
Chen T, Gao F, Feng S, Yang T and Chen M:
MicroRNA-370 inhibits the progression of non-small cell lung cancer
by down-regulating oncogene TRAF4. Oncol Rep. 34:461–468.
2015.PubMed/NCBI
|
|
18
|
Cantley LC and Neel BG: New insights into
tumor suppression: PTEN suppresses tumor formation by restraining
the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA.
96:4240–4245. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yo YT, Shieh GS, Hsu KF, Wu CL and Shiau
AL: Licorice and licochalcone-A induce autophagy in LNCaP prostate
cancer cells by suppression of Bcl-2 expression and the mTOR
pathway. J Agric Food Chem. 57:8266–8273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lev Bar-Or R, Maya R, Segel LA, Alon U,
Levine AJ and Oren M: Generation of oscillations by the p53-Mdm2
feedback loop: A theoretical and experimental study. Proc Natl Acad
Sci USA. 97:11250–11255. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoshikawa T, Aoyama T, Tanabe K, Nishikawa
K, Ito Y, Hayashi T, Cho H, Miyashita Y, Tsuburaya A and Sakamoto
J: Feasibility and safety of transhiatal approach and D2 total
gastrectomy after neoadjuvant chemotherapy for adenocarcinoma of
the esophago-gastric junction: A subset analysis of the COMPASS
trial. Dig Surg. 33:424–430. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Burkitt MD, Varro A and Pritchard DM:
Importance of gastrin in the pathogenesis and treatment of gastric
tumors. World J Gastroenterol. 15:1–16. 2009. View Article : Google Scholar :
|
|
23
|
Kozomara A and Griffiths-Jones S: miRBase:
Integrating microRNA annotation and deep-sequencing data. Nucleic
Acids Res. 39(Database): D152–D157. 2011. View Article : Google Scholar :
|
|
24
|
Wojcicka A, Swierniak M, Kornasiewicz OW,
Maciag M, Kolanowska M, Kotlarek M, Gornicka B, Koperski L,
Niewinski G, et al: Next generation sequencing reveals microRNA
isoforms in liver cirrhosis and hepatocellular carcinoma. Int J
Biochem Cell Biol. 53:208–217. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nielsen CB, Shomron N, Sandberg R,
Hornstein E, Kitzman J and Burge CB: Determinants of targeting by
endogenous and exogenous microRNAs and siRNAs. RNA. 13:1894–1910.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jazdzewski K, Boguslawska J, Jendrzejewski
J, Liyanarachchi S, Pachucki J, Wardyn KA, Nauman A and de la
Chapelle A: Thyroid hormone receptor beta (THRB) is a major target
gene for microRNAs deregulated in papillary thyroid carcinoma
(PTC). J Clin Endocrinol Metab. 96:E546–E553. 2011. View Article : Google Scholar
|
|
27
|
Courtney KD, Corcoran RB and Engelman JA:
The PI3K pathway as drug target in human cancer. J Clin Oncol.
28:1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Song MS, Salmena L and Pandolfi PP: The
functions and regulation of the PTEN tumour suppressor. Nat Rev Mol
Cell Biol. 13:283–296. 2012.PubMed/NCBI
|
|
29
|
Downes CP, Perera N, Ross S and Leslie NR:
Substrate specificity and acute regulation of the tumour suppressor
phosphatase, PTEN. Biochem Soc Symp. 74:69–80. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kong D and Yamori T: Advances in
development of phosphatidylinositol 3-kinase inhibitors. Curr Med
Chem. 16:2839–2854. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Roy S, Yu Y, Padhye SB, Sarkar FH and
Majumdar AP: Difluorinated-curcumin (CDF) restores PTEN expression
in colon cancer cells by down-regulating miR-21. PLoS One.
8:e685432013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kunze D, Wuttig D, Fuessel S, Kraemer K,
Kotzsch M, Meye A, Grimm MO, Hakenberg OW and Wirth MP: Multitarget
siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in
bladder cancer cells. Anticancer Res. 28B:2259–2263. 2008.
|
|
33
|
Wang YB, Qin J, Zheng XY, Bai Y, Yang K
and Xie LP: Diallyl trisulfide induces Bcl-2 and
caspase-3-dependent apoptosis via downregulation of Akt
phosphorylation in human T24 bladder cancer cells. Phytomedicine.
17:363–368. 2010. View Article : Google Scholar
|
|
34
|
Bouska A, Lushnikova T, Plaza S and
Eischen CM: Mdm2 promotes genetic instability and transformation
independent of p53. Mol Cell Biol. 28:4862–4874. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Clegg HV, Itahana K and Zhang Y: Unlocking
the Mdm2-p53 loop: Ubiquitin is the key. Cell Cycle. 7:287–292.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yamashita SI, Masuda Y, Yoshida N,
Matsuzaki H, Kurizaki T, Haga Y, Ikei S, Miyawaki M, Kawano Y,
Chujyo M, et al: p53AIP1 expression can be a prognostic marker in
non-small cell lung cancer. Clin Oncol (R Coll Radiol). 20:148–151.
2008. View Article : Google Scholar
|
|
37
|
Iwakuma T and Lozano G: MDM2, an
introduction. Mol Cancer Res. 1:993–1000. 2003.
|
|
38
|
Günther T, Schneider-Stock R, Häckel C,
Kasper HU, Pross M, Hackelsberger A, Lippert H and Roessner A: Mdm2
gene amplification in gastric cancer correlation with expression of
Mdm2 protein and p53 alterations. Mod Pathol. 13:621–626. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Granville CA, Memmott RM, Gills JJ and
Dennis PA: Handicapping the race to develop inhibitors of the
phosphoinositide 3-kinase/Akt/mammalian target of rapamycin
pathway. Clin Cancer Res. 12:679–689. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Markman B, Atzori F, Pérez-García J,
Tabernero J and Baselga J: Status of PI3K inhibition and biomarker
development in cancer therapeutics. Ann Oncol. 21:683–691. 2010.
View Article : Google Scholar
|
|
41
|
Karar J and Maity A: PI3K/AKT/mTOR pathway
in angiogenesis. Front Mol Neurosci. 4:512011. View Article : Google Scholar : PubMed/NCBI
|
